不同剂量米非司酮用于子宫肌瘤合并贫血患者对性激素水平的影响

doi:10.3969/j.issn.1671-7171.2023.09.025

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1144 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨不同剂量米非司酮用于子宫肌瘤合并贫血患者对性激素水平的影响。【方法】选取蒲城县医院2019年3月至2021年3月收治的90例子宫肌瘤合并贫血患者,按照随机数字表法分为观察组和对照组,每组45例。对照组术前采用大剂量米非司酮(20 mg/次)治疗,观察组术前采用小剂量米非司酮(10 mg/次)治疗。比较两组患者手术时间、术中出血量、住院天数、术后24 h血红蛋白含量、用药后不良反应发生情况及治疗前后性激素[促黄体生成素(LH)、孕酮(P)、促卵泡激素(FSH)、雌二醇(E₂)]水平、子宫肌瘤直径、子宫体积、生活质量量表(QOL)评分。【结果】两组患者手术时间、术中出血量、住院天数、术后24 h血红蛋白量比较,差异无统计学意义(P>0.05);两组患者治疗后LH、P、FSH、E₂水平均低于同组治疗前,差异有统计学意义(P<0.05);两组患者治疗后肌瘤直径、子宫体积均小于同组治疗前,QOL评分均高于同组治疗前,差异有统计学意义(P<0.05);观察组患者用药后不良反应发生率(15.56%)明显低于对照组(35.56%),差异有统计学意义(P<0.05)。【结论】子宫肌瘤合并贫血患者术前应用小剂量米非司酮可有效降低性激素水平,减小肌瘤体积,且安全性高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	董莉君
	王薇

关键词 ：平滑肌瘤/并发症, 贫血/并发症, 米非司酮/投药和剂量, 性腺甾类激素

Abstract：【Objective】To investigate the effect of different doses of mifepristone on sex hormone levels in patients with Uterine fibroid and anemia.【Methods】From March 2019 to March 2021,90 patients with Uterine fibroid and anemia in the Pucheng County Hospital were selected and divided into observation group and control group according to random number table,with 45 cases in each group. The control group received high-dose mifepristone (20 mg/dose) treatment before surgery,while the observation group received low-dose mifepristone (10 mg/dose) treatment before surgery. The operation time,intraoperative blood loss,hospital stay,hemoglobin content 24 hours after operation,adverse reactions after medication,levels of sex hormones [luteinizing hormone (LH),progesterone (P),Follicle-stimulating hormone (FSH),estradiol (E₂)],diameter of Uterine fibroid,uterine volume,and quality of life scale (QOL) scores were compared between the two groups.【Results】There was no statistically significant difference (P>0.05) between the two groups in terms of surgical time,intraoperative bleeding volume,length of hospital stay,and postoperative 24 hour hemoglobin levels; The levels of LH,P,FSH,and E₂ in the two groups of patients after treatment were lower than those in the same group before treatment,and the difference was statistically significant (P<0.05); After treatment,the diameter of fibroids and uterine volume of the two groups of patients were smaller than that before treatment,and the QOL scores was higher than that before treatment,with a statistically significant difference (P<0.05); The incidence of adverse reactions after medication in the observation group (15.56%) was significantly lower than that in the control group (35.56%),with a statistically significant difference (P<0.05).【Conclusion】Preoperative use of low-dose mifepristone in patients with Uterine fibroid and anemia can effectively reduce the level of sex hormones,reduce the volume of leiomyoma,and has high safety.

Key words： Leiomyoma/CO Anemia/CO Mifepristone/AD Gonadal Steroid Hormones

收稿日期: 2022-09-21

中图分类号:

R711.74

通讯作者: *E-mail:13708241704@163.com

引用本文:

董莉君, 王薇. 不同剂量米非司酮用于子宫肌瘤合并贫血患者对性激素水平的影响[J]. 医学临床研究, 2023, 40(9): 1371-1374.
DONG Lijun, WANG Wei. Effects of Different Doses of Mifepristone on Sex Hormone Levels in Patients with Uterine Fibroid and Anemia. JOURNAL OF CLINICAL RESEARCH, 2023, 40(9): 1371-1374.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.09.025 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I9/1371

[1] 王丽燕,罗宇迪,王兴红. 子宫肌瘤合并月经过多的危险因素分析及风险预测模型构建[J].中国计划生育和妇产科,2021,13(3):43-47.
[2] 徐书峰. 子宫肌瘤的介入治疗进展[J].实用放射学杂志,2020,36(6):998-1000.
[3] 张定红,王宏丽.不同剂量米非司酮治疗子宫肌瘤的临床疗效比较[J].中国计划生育学杂志,2020,28(11):1821-1823.
[4] 华芬芬,严礼平.子宫肌瘤与正常子宫肌层中14-3-3γ蛋白的表达及与雌、孕激素受体、临床病理参数相关性研究[J].中国性科学,2020,29(11):91-95.
[5] 武群英,王晓誉.米非司酮不同配伍方式用于瘢痕子宫中期妊娠引产的疗效及安全性比较[J].医学临床研究,2021,38(10):1493-1496.
[6] 苗华艳. 现代子宫肌瘤诊断与治疗[M]. 长春:吉林科学技术出版社,2011:103-104.
[7] SDERSTRM L,BERGKVIST L,ROSENBLAD A. Oral nutritional supplement use is weakly associated with increased subjective health-related quality of life in malnourished older adults: a multicentre randomised controlled trial[J].Br J Nutr,2022,127(1):103-111.
[8] SHIKHA S,NEERU G,EKTA S,et al. Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman[J].J Mid-life Health,2020,4(1):22-26.
[9] 郑雨,戴秋香,梁菊,等.米非司酮联合桂枝茯苓胶囊对子宫肌瘤患者血清雌、孕激素及氧化应激因子水平的影响[J].医学临床研究,2020,37(7):1008-1010.
[10] 卞美璐,黄敏丽,张震宇,等.低剂量米非司酮用于子宫肌瘤的术前治疗多中心随机双盲、安慰剂、平行对照研究[J].中华妇产科杂志,2021,56(5):317-327.
[11] CARBONELL J,ACOSTA R,MARRERO AG,et al. Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial[J].Int J Women's Health,2013,19(5):115-124.
[12] 封全灵,熊祯祯,王智霆,等. 米非司酮对孕激素受体M阳性子宫肌瘤细胞增殖、凋亡的影响[J].山东医药,2017,57(3):13-15.
[13] 刘瑞莲. 不同剂量米非司酮治疗子宫肌瘤的临床探讨[J].中外医疗,2016,35(7):123-124.
[14] 张志恒,谢卓,陈娟.曲普瑞林联合不同剂量米非司酮在子宫肌瘤治疗中的应用价值研究[J].中国性科学,2021,30(2):85-88.
[15] 李海艳,唐晓慧. 米非司酮不同剂量用药方案对子宫肌瘤的疗效及安全性分析[J].沈阳药科大学学报,2021,38(1):66.